Clinical remission of an inoperable malignant insulinoma by the combination treatment with octreotide and everolimus. (11th January 2019)

• Record Type: Journal Article
• Authors: Akahori, Hiroshi
• Is Part Of: Journal of general and family medicine. Volume 20:Number 3(2019)
• Page Start: 107
• Page End: 110
• Publication Date: 2019-01-11
• Subjects: everolimus -- malignant insulinoma -- mammalian target of rapamycin -- multiple liver metastases -- octreotide -- somatostatin receptor; Primary care (Medicine) -- Periodicals; Family medicine -- Periodicals; Family Practice; Primary Health Care; Japan; Periodicals; 610
• DOI: 10.1002/jgf2.235
• Languages: English
• ISSNs: 2189-7948

Abstract

Abstract: We report a 52‐year‐old woman with inoperable malignant insulinoma with multiple liver metastases. Histological examination of biopsy specimens from the pancreatic and hepatic lesions revealed pancreatic neuroendocrine tumor (pNET), G2. The tumor cells were positive for somatostatin receptor (SSTR) 2, 5, and the mammalian target of rapamycin (mTOR). Monthly intramuscular administration of octreotide LAR and once‐daily oral administration of everolimus combination treatment markedly reduced the sizes of liver metastases, and hypoglycemia was well controlled. Combination treatment with somatostatin analog and mTOR inhibitor may be another effective approach in inoperable metastatic malignant insulinoma. Abstract : Monthly intramuscular administration of octreotide LAR and once‐daily oral administration of everolimus combination treatment markedly reduced the sizes of liver metastases, and hypoglycemia was well controlled. Combination treatment with somatostatin analog and mTOR inhibitor may be another effective approach in inoperable metastatic malignant insulinoma.